Dr Antonio Passaro (European Institute of Oncology, Milan, Italy), Prof Nicolas Girard (Institut Curie, Paris, France), Prof Raffaele Califano (The Christie NHS Foundation Trust, Manchester, UK) and Dr Anna Minchom (Institute of Cancer Research, London, UK) discuss the latest in EGFR positive NSCLC.

The discussion highlights the latest updates from ELCC 2025, focusing on the MARIPOSA trial and its significant findings on overall survival with amivantamab plus lazertinib.

The panel also talks about the SAVANNAH and ORCHARD trials.
 
Prof Girard shares insights from the COCOON trial that emphasise dermatological side effects and prophylactic management.

The discussion includes subcutaneous administration of amivantamab from the PALOMA-2 study, future strategies for resistant cases, and the phase II ETOP AMAZE-lung trial's findings, concluding with reflections on improving quality of life for patients.